Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies
Phase 3
192
about 4 years
18+
1 site in KS
About this study
Researchers are testing whether a higher dose of immunotherapy (every 6 weeks Pembrolizumab 400mg and every 4 weeks Nivolumab 480mg) causes more immune-related adverse events (irAEs) compared to a lower dose (every 3 weeks Pembrolizumab 200mg and every 2 weeks Nivolumab 240mg). The trial is for adults with solid tumors.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Nivolumab
- 2.Take Pembrolizumab
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
nivolumab (Immune checkpoint inhibitor; blocks PD-1 receptor on T cells), pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
infusion
Primary: Proportions of grade ≥3 immune related adverse events (irAEs) between the two arms in each cohort
Secondary: All grades of immune related adverse events (irAEs), Disease-Free Survival (DFS), Overall Response Rate (ORR), Overall Survival (OS), Progression-Free Survival (PFS), Time of treatment discontinuation due to immune related adverse events (irAEs), Time to resolution of immune related adverse events (irAEs)
Oncology